利用肝炎病毒核心蛋白作为疫苗平台。
Use of hepadnavirus core proteins as vaccine platforms.
机构信息
Vaccine Research Institute of San Diego, San Diego, CA 92121, USA.
出版信息
Expert Rev Vaccines. 2009 Nov;8(11):1565-73. doi: 10.1586/erv.09.121.
Abstract
The first virus-like particle to be tested for use as a vaccine carrier was based on the hepatitis B virus nucleocapsid protein. This viral subunit, while not infectious on its own, is a 36-nm particle that is highly immunogenic during a natural infection. The self-assembly and high degree of immunogenicity is maintained when expressed as a recombinant protein and, moreover, can confer a high degree of immunogenicity on foreign antigens linked to the particle, either chemically or genetically. This review describes the current state of the hepadnaviral core protein as a vaccine carrier.
摘要
作为疫苗载体而进行测试的首个类病毒颗粒是基于乙型肝炎病毒核衣壳蛋白。这种病毒亚单位本身并无感染性，但在自然感染过程中是一种 36nm 的颗粒，具有高度的免疫原性。当作为重组蛋白表达时，其自组装和高度免疫原性得以保持，而且，通过化学或遗传方法与颗粒相连的外来抗原也能赋予高度的免疫原性。本综述描述了作为疫苗载体的肝病毒核心蛋白的现状。
相似文献
1
Use of hepadnavirus core proteins as vaccine platforms.利用肝炎病毒核心蛋白作为疫苗平台。
Expert Rev Vaccines. 2009 Nov;8(11):1565-73. doi: 10.1586/erv.09.121.
2
Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.乙肝病毒核心抗原与e抗原：免疫识别及作为疫苗载体部分的应用
Intervirology. 1996;39(1-2):104-10. doi: 10.1159/000150481.
3
4
Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen.含有人类免疫缺陷病毒1型核心抗原表位的重组乙肝病毒核心颗粒的免疫原性
Arch Virol. 1992;126(1-4):321-8. doi: 10.1007/BF01309705.
5
[Hepatitis B virus core protein as an epitope vaccine carrier: a review].[乙肝病毒核心蛋白作为一种表位疫苗载体：综述]
Sheng Wu Gong Cheng Xue Bao. 2010 Apr;26(4):431-8.
6
Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.乙型肝炎病毒核心抗原作为疫苗载体部分：I. 外源表位的呈现
J Biotechnol. 1996 Jan 26;44(1-3):91-6. doi: 10.1016/0168-1656(95)00118-2.
7
Hepatitis B core-based virus-like particles to present heterologous epitopes.基于乙型肝炎核心的病毒样颗粒来呈现异源表位。
Expert Rev Vaccines. 2013 Feb;12(2):183-98. doi: 10.1586/erv.12.150.
8
New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge.携带汉坦病毒（普马拉血清型）表位的新型嵌合乙型肝炎病毒核心颗粒：免疫原性及对病毒攻击的保护作用。
J Biotechnol. 1999 Aug 20;73(2-3):141-53. doi: 10.1016/s0168-1656(99)00117-0.
9
The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.插入乙肝病毒核心颗粒中的异源表位的位置决定了它们的免疫原性。
J Virol. 1992 Jan;66(1):106-14. doi: 10.1128/JVI.66.1.106-114.1992.
10
The core antigen of hepatitis B virus as a carrier for immunogenic peptides.乙型肝炎病毒核心抗原作为免疫原性肽的载体。
Biol Chem. 1999 Mar;380(3):277-83. doi: 10.1515/BC.1999.038.
引用本文的文献
1
A Lyophilizable Nanoparticle Vaccine Specific for a Novel Linear Neutralizing Epitope in the α2-α3 Helices of Domain 3 of Lethal Factor from .一种针对来自致死因子第3结构域α2-α3螺旋中新型线性中和表位的冻干纳米颗粒疫苗。
Toxins (Basel). 2025 Aug 20;17(8):422. doi: 10.3390/toxins17080422.
2
A VLP vaccine platform comprising the core protein of hepatitis B virus with N-terminal antigen capture.一种包含具有N端抗原捕获功能的乙肝病毒核心蛋白的病毒样颗粒疫苗平台。
Int J Biol Macromol. 2025 May;305(Pt 2):141152. doi: 10.1016/j.ijbiomac.2025.141152. Epub 2025 Feb 15.
3
Chemically Tagging Cargo for Specific Packaging inside and on the Surface of Virus-like Particles.化学标记病毒样颗粒内部和表面特定包装的货物。
ACS Nano. 2024 Aug 13;18(32):21024-21037. doi: 10.1021/acsnano.4c02056. Epub 2024 Aug 1.
4
Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus.携带呼吸道合胞病毒表位的基于嗜肝DNA病毒核心蛋白的嵌合病毒样颗粒的设计
NPJ Vaccines. 2024 Mar 19;9(1):62. doi: 10.1038/s41541-024-00855-7.
5
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.引入负载佐剂的颗粒状乙型肝炎核心抗原作为治疗性乙型肝炎疫苗的替代成分。
JHEP Rep. 2023 Dec 30;6(4):100997. doi: 10.1016/j.jhepr.2023.100997. eCollection 2024 Apr.
6
Oral and Subcutaneous Immunization with a Plant-Produced Mouse-Specific Zona Pellucida 3 Peptide Presented on Hepatitis B Core Antigen Virus-like Particles.用呈递于乙型肝炎核心抗原病毒样颗粒上的植物生产的小鼠特异性透明带3肽进行口服和皮下免疫
Vaccines (Basel). 2023 Feb 17;11(2):462. doi: 10.3390/vaccines11020462.
7
Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition.展示保守毒素表位的病毒样颗粒可刺激多特异性的、能够识别蛇毒的鼠抗体反应。
Sci Rep. 2022 Jul 5;12(1):11328. doi: 10.1038/s41598-022-13376-x.
8
Immunization with GP1 but Not Core-like Particles Displaying Isolated Receptor-Binding Epitopes Elicits Virus-Neutralizing Antibodies against Junín Virus.用GP1而非展示孤立受体结合表位的类核心颗粒进行免疫接种可引发针对胡宁病毒的病毒中和抗体。
Vaccines (Basel). 2022 Jan 22;10(2):173. doi: 10.3390/vaccines10020173.
9
Protein nanoparticles directed cancer imaging and therapy.蛋白质纳米颗粒用于癌症成像与治疗。
Nano Converg. 2022 Jan 8;9(1):2. doi: 10.1186/s40580-021-00293-4.
10
Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.基于乙肝核心的病毒样颗粒：植物疫苗开发的一个平台。
Biotechnol Rep (Amst). 2021 Feb 28;29:e00605. doi: 10.1016/j.btre.2021.e00605. eCollection 2021 Mar.
本文引用的文献
1
Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.工程改造到人乳头瘤病毒L1衣壳蛋白外表面暴露的螺旋4环区域中的异源表位的抗原呈递。
Virol J. 2009 Jun 18;6:81. doi: 10.1186/1743-422X-6-81.
2
Interaction of the hepatitis B core antigen and the innate immune system.乙型肝炎核心抗原与固有免疫系统的相互作用。
J Immunol. 2009 Jun 1;182(11):6670-81. doi: 10.4049/jimmunol.0803683.
3
Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design.番茄丛矮病毒（TBSV），一种用于多价展示抗原表位和疫苗设计的通用平台。
Virology. 2009 May 25;388(1):185-90. doi: 10.1016/j.virol.2009.02.051. Epub 2009 Apr 2.
4
Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.甲型流感病毒M2肽作为重组病毒样颗粒或结合疫苗在小鼠和猴子中的免疫原性比较评估。
Vaccine. 2009 Feb 25;27(9):1440-7. doi: 10.1016/j.vaccine.2008.12.034. Epub 2009 Jan 13.
5
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases.免疫药物：用于慢性病的基于病毒样颗粒的治疗性疫苗。
Annu Rev Pharmacol Toxicol. 2009;49:303-26. doi: 10.1146/annurev-pharmtox-061008-103129.
6
Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins.核心蛋白内部切割使乙肝病毒衣壳保持完整，并增强其展示异源全链蛋白的能力。
J Biol Chem. 2008 Nov 28;283(48):33508-15. doi: 10.1074/jbc.M805211200. Epub 2008 Sep 30.
7
The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens.B细胞受体决定Toll样受体9的亚细胞定位，导致对含DNA抗原的高反应性。
Immunity. 2008 Jun;28(6):799-809. doi: 10.1016/j.immuni.2008.03.019. Epub 2008 May 29.
8
Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.基于与木瓜花叶病毒（PapMV）疫苗平台融合的M2e肽开发通用甲型流感疫苗。
Vaccine. 2008 Jun 25;26(27-28):3395-403. doi: 10.1016/j.vaccine.2008.04.052. Epub 2008 May 12.
9
Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.含恶性疟原虫环子孢子蛋白表位的铝佐剂乙肝核心病毒样颗粒的I期试验
PLoS One. 2008 Feb 6;3(2):e1556. doi: 10.1371/journal.pone.0001556.
10
Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.将啮齿动物嗜肝DNA病毒核心蛋白用作疫苗平台的优势。
Vaccine. 2007 Feb 19;25(9):1593-606. doi: 10.1016/j.vaccine.2006.11.013. Epub 2006 Nov 17.
Zotero 插件